GT-02287, a potential therapy for Parkinson’s disease, showed promising results in a Phase 1 clinical trial involving healthy volunteers,…
Articles by Margarida Maia, PhD
Patients treated with bemdaneprocel, a cell therapy that Bluerock Therapeutics is developing for Parkinson’s disease, continue to spend…
Pramipexole, the active ingredient in the Parkinson’s disease therapy Mirapex, appears to overactivate a brain region known as…
Parkin, a protein linked to Parkinson’s disease that’s lost in certain types of cancer, triggers the release of signaling…
Ten consecutive weeks of either high-intensity interval training or continuous training, which is moderate in intensity, effectively eased disease…
Subcutaneous, or under-the-skin, injections of COYA 302, a combination therapy in development by Coya Therapeutics, were found to reduce…
Note: This story was updated Sept. 16, 2024, to correct that A-dopamine is a form of dopamine. Levodopa, a…
Rune Labs has launched StrivePD-AI, a new feature in its StrivePD app that uses generative artificial intelligence (GenAI) to…
The American Parkinson Disease Association (APDA) has awarded a total of $2.6 million for the 2024-2025 funding year, to…
The U.S. Food and Drug Administration (FDA) is encouraging scientists and drug developers to use an alpha-synuclein seed amplification assay…